In addition, Bruce et al. found that BCL2 antagonist administration partially prevented fibrogenesis in intestinal fibroblasts and reduced the expression of TGF-β-induced factors involved in the differentiation of myofibroblasts; therefore, BCL2 might be a potential treatment option against Crohn’s disease-associated fibrosis [26]. Here, BCL2 is linked to Crohn disease.